Phase II
Evaluating Biomarker-Guided Medication Changes in Kidney Transplant Patients
- Study HIC#:2000033724
- Last Updated:08/12/2024
- The purpose of this study is to learn whether ORENCIAÒ is as good as tacrolimus in preventing rejection, and whether there are other benefits or harms associated with ORENCIAÒ treatment.
- Age18 years - 70 years
Contact Us
For more information about this study, including how to volunteer, contact:
Cameron Groshek
- Phone Number: 1-203-737-7683
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
- Candidates for or recipients of a first kidney transplant from either a living or deceased donor who have received or are eligible to receive an ABO-compatible kidney transplant (including A2 to B) within the past 14 days.
